Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 38

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
(600,888)  (1,354,357)Fair value loss on investments in equity securities  -   (119,499)  -   (119,499)Provision for expected credit losses   -   (215,942)  -   (215,942)TOTAL OPERATING EXPENSES  (386,852)  (2,405,119)  (638,090)  (3,430,061)                 LOSS FROM OPERATIONS  (305,980)  (988,150)  (638,090)  (1,932,220)                 FINANCE COSTS  (9,752)  (6,266)  (252)  (16,270)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(315,732) $(994,416) $(638,342) $(1,948,490)

 29Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   As of September 30, 2025              Segment assets  $2,374,976  $4,766,502  $479,750  $7,621,228                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets  -   35,994   -   35,994    Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   As of December 31, 2024              Segment assets  $2,652,754  $6,788,302  $992,792  $10,433,848                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets